Summary
The redistribution of platelet membrane glycoprotein IV (GPIV) and the release of intracellular α-granule thrombospondin (TSP) were examined and the inhibition of β-thromboglobulin (β-TG) and platelet factor 4 (PF4) in patients with chronic myelogenous leukemia (CML) was observed and quantitation of β-TG and PF4 in sera was conducted. GPIV in inactive platelet from CML was 36080± 17010 molecules/platelet as compared with 13190±4810 from the controls (P< 0.01). No abnormality was found in the distribution of platelet membrane GPIb and GPIIb/III,(P> 0.05). The GPIV redistribution on active platelet membrane induced thrombin (IU/ml) from CML and healthy donors was 44320 ±32310 and 22800± 12700 molecules/platelet respectively (P< 0.01). The difference in the release of intracellular α-granule TSP between CML and the control group was not found (P> 0.05). There was no direct correlation between GPIV expression and TSP binding after platelet activation. The high levels of β-TG and PF4 in sera inhibited release of intracellular α-granule TSPin vitro. These results indicate that the abnormality of platelet membrane GPIV is a common marker in CML, therefore the specific increase of platelet GPIV in patients with CML may be a useful tool for the diagnosis and monitoring of the platelet dysfunction. The release of internal TSP pools is hindered by either β-TG or PF4 in sera.
Similar content being viewed by others
References
WcGregor J L, Catimel B, Parmentier Set al. Rapid purification and partial characterization of human platelet glycoprotein IIIb: interaction with thrombospondin and its role in platelet aggregation. J Biol Chem, 1989, 264:501
Thibert V, Bellucci S, Edelman Let al. Quantitation of platelet glycoprotein IV (CD36) in healthy subjects and in patient with essential thrombocythemia using an immunocapture assay. Thrombosis and Haemostasis, 1992, 68:600
Legrand C, Dubernard V, Kieffer Net al. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem, 1988, 171:393
c-myc c-sis. 1995,16:122
Beiso P, Pidard D, Fournier Det al. Studies on the interaction of platelet glycoprotein Ib/Ia and glycoprotein IV with fibrinogen and thrombospondin: A new immunochemical approach. Biochim Biophys Acta, 1990, 1033:7
Clezardin P, McGregor J L, Dechavanne Met al. Platelet membrane glycoprotein abnormalitities in patient with myeloproliferative disorders and secondary thrombocytosis. Bri J Hacmatol, 1985, 60:331
Thibert V, Bellucci S.Cristofari Met al. Increased platelet CD36 constitutes a common marker in myeloproliferation disorders. Bri J Haematol, 1995, 91:618
Berger G, Caen J P, Bernndt M Cet al. Ultrastructural demonstration of CD36 in the α-granule membrane of human platelet and megakaryocytes. Blood, 1993, 82:3034
Han Z C, Sensebe L, Abgrall JFet al. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood, 1990, 75:1234
Abgrall J F, Han Z C, Sensebe Let al. Inhibitory affect of highly purified human β-thromboglobulinin vitro human megakaryocyte colony formation. Exp Hematol, 1991, 19:202
Author information
Authors and Affiliations
Additional information
This project was supported by the National Natural Science Foundation of China (No. 39370322).
Rights and permissions
About this article
Cite this article
Dongxu, L., Di, S., Ping, Z. et al. Redistribution of platelet membrane glycoprotein iv and release of intracellular α-granule thrombospondin in patients with chronic myelogenous leukemia. Current Medical Science 17, 21–24 (1997). https://doi.org/10.1007/BF02887996
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02887996